Skip to main content
Log in

Assessing cost effectiveness of second-line HIV regimens in Africa

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Boyer S, et al. Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa. PharmacoEconomics-Open : 4 Jul 2019. Available from: URL: https://doi.org/10.1007/s41669-019-0157-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Assessing cost effectiveness of second-line HIV regimens in Africa. PharmacoEcon Outcomes News 832, 5 (2019). https://doi.org/10.1007/s40274-019-6031-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6031-2

Navigation